Research Topics
Species | David M JackmanSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Small-cell lung cancerDavid M Jackman
Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Lancet 366:1385-96. 2005..For patients who survive long term, careful monitoring for development of a second primary tumour is necessary, with further investigation and treatment as appropriate...
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsDavid M Jackman
Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 15:5267-73. 2009....
Current options for systemic therapy in mesotheliomaDavid M Jackman
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Semin Thorac Cardiovasc Surg 21:154-8. 2009..This article surveys the current clinical landscape of systemic therapies in mesothelioma and explores the impact of both conventional and targeted agents...- The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutationsStephanie Heon
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Clin Cancer Res 18:4406-14. 2012.... - New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapyMizuki Nishino
Department of Radiology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02116, USA
AJR Am J Roentgenol 195:W221-8. 2010..1) to the original guidelines (RECIST 1.0) for advanced non-small cell lung cancer (NSCLC) after erlotinib therapy and to evaluate the impact of the new CT tumor measurement guideline on response assessment... - Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinibDaniel B Costa
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Clin Cancer Res 14:7060-7. 2008..Our goal was to determine the effects of erlotinib 150 mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib is given at a higher biologically active dose than gefitinib... - Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinibStephanie Heon
Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 16:5873-82. 2010..However, there are incomplete data about their impact on the development and control of CNS metastases... - Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibDavid M Jackman
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 24:4517-20. 2006 - The introduction of systematic genomic testing for patients with non-small-cell lung cancerStephanie Cardarella
Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
J Thorac Oncol 7:1767-74. 2012..We report the implementation of systematic prospective genotyping for somatic alterations in BRAF, PIK3CA, HER2, and ALK, in addition to EGFR and KRAS, in NSCLC patients at the Dana-Farber Cancer Institute... - EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistryLynette M Sholl
Department of Pathology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
Am J Clin Pathol 133:922-34. 2010..Thus, EGFR sequence analysis was the only method useful for predicting response and progression-free survival following TKI therapy in NSCLC... - Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancersKimio Yonesaka
Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 14:6963-73. 2008..The determinant(s) of efficacy of EGFR-targeted therapies in EGFR wild-type cancers is not well defined... - Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesotheliomaDavid M Jackman
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 113:808-14. 2008..These agents have activity in non-small cell lung cancer, but their role in mesothelioma is unclear. The primary endpoint is response rate. Secondary endpoints include time to progression, survival, and toxicity... - Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancerDavid M Jackman
Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 25:760-6. 2007..The secondary end points include radiographic response rate, time to progression (TTP), toxicity, and symptom improvement... - Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitorsMizuki Nishino
Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave Boston MA, 02215, USA Department of Radiology, Brigham and Women s Hospital, 75 Francis St Boston MA, 02215, USA Electronic address
Lung Cancer 79:283-8. 2013..TKIs are often continued beyond progressive disease by RECIST. We investigated the practice of continuing EGFR-TKIs after RECIST-PD via CT findings... - Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibDavid M Jackman
Lowe Center of Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 12:3908-14. 2006..Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib... - Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumabMizuki Nishino
Department of Radiology, Dana Farber Cancer Institute and Brigham and Womens Hospital, Boston, MA 02215 5450, USA
Cancer Imaging 12:225-35. 2012.... - Imaging of lung cancer in the era of molecular medicineMizuki Nishino
Department of Imaging, Dana Farber Cancer Institute, Boston, MA 02115, USA
Acad Radiol 18:424-36. 2011..Knowledge of the molecular basis of lung cancer is essential for radiologists to properly interpret imaging and assess response to therapy. Quantitative and functional imaging helps assessing the biologic behavior of lung cancer... - Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertionsGeoffrey R Oxnard
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
J Thorac Oncol 8:179-84. 2013..Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies... - Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLCRaymond H Mak
Harvard Radiation Oncology Program, Boston, Massachusetts, USA
Oncologist 16:886-95. 2011..Epidermal growth factor receptor (EGFR) mutations identify a unique biological subtype of non-small cell lung cancer (NSCLC). Treatment outcomes for EGFR-mutant locally advanced NSCLC patients have not been well described... - Treatment of peritoneal mesothelioma in pediatric patientsLeigh Anne Cioffredi
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Pediatr Blood Cancer 52:127-9. 2009..Treatment was well tolerated, and three of these patients have achieved long-term survival. The fathers of three of the patients worked in the construction industry and may have been the source of indirect asbestos exposure... - CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical toolMizuki Nishino
Department of Imaging, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
Acad Radiol 18:54-62. 2011..Determine inter- and intraobserver variability of computed tomography (CT) tumor volume measurements in advanced non-small-cell lung cancer (NSCLC) patients treated in a Phase II clinical trial using chest CT... - Pathologic characteristics of NUT midline carcinoma arising in the mediastinumAndrew G Evans
Department of Pathology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
Am J Surg Pathol 36:1222-7. 2012..NMC should be considered in the differential diagnosis of any poorly differentiated epithelioid mediastinal tumor, regardless of age... - Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatmentDavid M Jackman
Dana Farber Cancer Institute, Boston, MA 02115, USA
Semin Respir Crit Care Med 26:342-52. 2005..This article reviews the epidemiology, risk factors, pathology, clinical presentation, and treatment of this disease. Special focus is paid to the emerging role of oral EGFR-TKIs in Bronchioloalveolar cell carcinoma... - Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancerMari Nakabayashi
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer 107:975-81. 2006..Although uncommon, additional durable responses occurred in some patients after dose escalation...